x
ServiziMenu principaleHome
Home > Programme > Programme
Print

Programme

THURSDAY, 2 NOVEMBER

9:00   Patient advocacy session: Direct patient involvement in ABC research
(Chairs: Bertha Aguilar Lopez, MX - Anna Cabanes, US - Shirley A. Mertz, US)
(Panellists: Bertha Aguilar Lopez, MX - Jonas Bergh, SE - Matthew J. Ellis, US - Shirley A. Mertz, US Danielle Spence AU - Nikhil Wagle, US)    
9:00   Sponsored satellite symposium (details are available here)
10:30   Coffee break
11:00   Patient advocacy session: Survivorship 101: Work, finances, home and emotional support (Chairs: Danni Manzi, UK - Gertrude Nakigudde, UG and Evi Papadopoulos, CY)
• Work means more than money (Evi Papadopoulos, CY)     
• Discusssion 
• The support of the other side 
• Discusssion 
• How can I swim in a storm (Gertrude Nakigudde, UG)
• Discusssion
11:00   Sponsored satellite symposium (details are available here)
12:30   Lunch
12:40   UICC invites participants to Room 1.06 by the exhibition area to the event: Chance to meet SPARC MBC Challenge awardees (details are available here)
13:30   Opening session (Chairs: Fatima Cardoso, PT and Larry Norton, US)  
• Welcome to Lisbon (Prof. Marcelo Rebelo de Sousa, President of the Portuguese Republic)
• Opening and introduction (Fatima Cardoso, PT)
• Keynote lecture: Living two roles: oncologist and patient (Bella Kaufman, IL)
14:30
  Long term remissions: Challenges and controversies (Chairs: Anna Cabanes, US and Olivia Pagani, CH)
• Management issues: How and until when to treat? (Christoph Thomssen, DE)
• Is family planning (fertility, adoption) out of the question? (Shani Paluch-Shimon, IL)
• Impact on legal and professional lives (Elizabeth Bergsten Nordström, SE)
• Discussion
15:25   Best abstract presentations (Chairs: Alberto Costa, IT/CH and Danielle Spence, AU)
• Analysis of the gaps on metastatic breast cancer global policies and advocacy efforts to support policy development across the patient journey (Maia Thrift-Perry, US)
• Impact of disease progression status on time to deterioration of patient reported health related quality of life in first line er+ her2-ve advanced/metastatic breast cancer patients in the PALOMA-2 study (Nadia Harbeck, DE)
• Effect of exercise on cardiovascular fitness and quality of life outcomes in advanced breast cancer patients (E. Oliveira, PT)
• Discussion
16:05   Coffee break
16:30
  Optimizing anti-HER-2 therapies for ABC (Chairs: Elzbieta Senkus, PL and Eric P. Winer, US)
• Optimal sequence with and without all availble agents (Ian E. Krop, US)
• Overcoming resistance to anti-HER2 therapies (Karen Gelmon, CA)
• Potential role of immunotherapy (Javier Cortés, ES)
• Will biosimilars become standard? (Smruti Koppikar, IN)
• Discussion
17:40   ABC Award and Lecture (Chair: L. Norton, US; Awardee: M. Mayer, US)
Silent voices speak: An advocate's journey
18:00
  Patient advocacy session: Registries, databases and statistical modelling: making MBC count (Chairs: Musa Mayer, US and Danielle Spence, AU)
• Introduction and Australia STAR project (Danielle Spence, AU)
• Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States (Musa Mayer, US)
• The new German Cancer Registry (Norbert Marschner, DE)
• Breast Cancer Care UK (Danni Manzi, UK)
• Discussion
18:00   Sponsored satellite symposium (details are available here)     
19:30   Welcome cocktail (included in the registration fee)   

FRIDAY, 3 NOVEMBER      

9:00   The new management of luminal ABC (Chairs: Bertha Aguilar Lopez, MX and Binghe Xu, CN)
• Best sequence of available therapies (Nadia Harbeck, DE)
• Management of new side effects (Carlos H. Barrios, BR)
• Mechanisms of resistance to endocrine and biological agents (Stephen R.D. Johnston, UK)
• Discussion
9:55   Coffee break
10:20
  Clinical challenges (Chairs: Jonas Bergh, SE and Renate Haidinger, DE)
• Metronomic chemotherapy: A good old friend (Nagi S. El Saghir, LB)
• Maintenance therapy (CT, ET, biologics) (Prudence A. Francis, AU)
• Oral drugs: Challenges for the oncology nurse (Christine B. Boers-Doets, NL)
• ABC elderly patient management (Laura Biganzoli, IT)
• Discussion  
11:30
  Inflammatory advanced breast cancer (Chairs: Maria João Cardoso, PT and Gertrude Nakigudde, UG)   
• Biology of inflammatory breast cancer (Frédérique Penault-Llorca, FR)
• Extensive cutaneous metastases: A separate entity? (Giuseppe Curigliano, IT)
• The role of different radiation techniques (Birgitte V. Offersen, DK) 
• Discussion
12:25   Lunch and poster session (details regarding posters are available at the bottom of this page)
13:30
  Lost in translation! (Chairs: Dian “CJ” M. Corneliussen-James, US and Daniel A. Vorobiof, ZA)
• Multigene testing: Aid or clinical nightmare (Fabrice André, FR )
• The role of ctDNA (Nicholas C. Turner, UK)
• Precision/personalized medicine: Hopes & hypes (George W. Sledge, US)
• Discussion  
14:25   Supportive and palliative care (Chairs: Matti S. Aapro, CH and Musa Mayer, US)
• Management of neurotoxicity (Matti S. Aapro, CH)
• Peritoneal carcinomatosis and ascites: Best practices (Véronique Diéras, FR)
• End-of-life communication: Patient and health care provider perspectives
- Part I (Lesley Fallowfield, UK)
- Part II (Musa Mayer, US)
• Discussion   
15:35   Coffee break  
16:00   A world of contrasts! (Chairs: Fatima Carsoso, PT and Shirley A. Mertz, US)
• Access to radiation worldwide (Mary K. Gospodarowicz, CA)
• Shortage of drugs: Solutions (Alexandru Eniu, RO)
• eHealth: Friend or foe (Timo Schinköthe, DE)
• Discussion
17:00   Management of triple negative ABC (Chairs: Shinji Ohno, JP and E. Papadopoulos, CY)
• What's new in biology (Aleix Prat, ES)
• The role of immunotherapy (Hope S. Rugo, US)
• New kids on the block: CDKi, ARi, PARPi (Lisa A. Carey, US)
• Discussion
18:00
  Patient advocacy session: ABC Advocacy: Managing side effects, sexual issues and fertility (Chairs: Dian “CJ” M. Corneliussen-James, US and Renate Haidinger, DE)
• How can physicians help to avoid or treat side effects? (Christoph Thomssen, DE)
• How can patients help to avoid or treat side effects? (Renate Haidinger, DE)
• Discussion
• Intimacy - Starting Anew (Dian “CJ” M. Corneliussen-James, US)
• Fertility -The Joys and the Risks (Dian “CJ” M. Corneliussen-James, US)
• Discussion
18:00   Sponsored satellite symposium (details are available here)

SATURDAY, 4 NOVEMBER

8:30   Consensus session (part I) (ABC4 chairs, scientific committee members and panellists)
10:30   Coffee break
11:00   Report from ABC Patient Advocacy Committee (Danielle Spence, AU)
11:15   Consensus session (part II) (ABC4 chairs, scientific committee members and panellists)

12:45-
13:00

  Close


A/V RECORDING DURING THE CONFERENCE IS PROHIBITED
 

SATURDAY, 4 NOVEMBER AND SUNDAY, 5 NOVEMBER 2017

ABC4 will be followed by the first meeting of the ABC Global Alliance that will be held across two half day sessions at the following times:
Part 1: Saturday, 4 November, from 15:00 to 17:30, and
Part 2 : Sunday, 5 November, from 8:30 to 13:00
The detailed programme will be published soon.

 

Poster session

BP: Best poster presentation; PO: Poster presentation

BP34     #Pacientesnocontrole (patients in control): Campaign to increase access to metastatic breast cancer (mbc) treatment in Brazil. Maira Caleffi, BR
PO66     Adverse events (AE) of targeted agents added to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis. Matteo Lambertini, BE
BP67     Characteristics of the metastatic breast cancer population with PIK3CA mutation in the randomized phase II study SAFIR02 breast (UCBG- 0105/1304). Claudia Lefeuvre-Plesse, FR
PO36     Fostering innovation in advocacy for metastatic breast cancer. Marina Teahon, CH
PO37     Public hearings and debate cycles for parliamentarians on breast cancer. Maira Caleffi, BR
PO38     A study of nursing provision and models of care for people diagnosed and living with metastatic breast cancer in Britain: what are the implications for the practice? and what role does patient advocacy play? Catherine Priestley, UK
PO39     Educate-empower-advocate: A new model for advocacy and creating change for women with metastatic breast cancer. MJ DeCoteau, CA
PO40     Patient navigation: Mitigating the surge of advanced breast cancer in sub-Saharan Africa. Runcie Chikeruba Wilson Chidebe, NG
PO41     BC III and IV treatment in Brazil: Differences between public health, supplementary health and iternational protocol recommendations. Maira Caleffi, BR
PO42     The unmet information, support and financial needs of women with metastatic breast cancer in Australia: results of two breast cancer network Australia studies. Danielle Spence, AU
PO43     Tanto por hacer. Eliza Puente, MX
PO44      Social media storytelling as an advocacy and support tool for people living with metastatic breast cancer. Janine Guglielmino, US
PO45     Breast cancer knowledge and quality of life among participants of a breast cancer support group in rural Ruwanda. Thomas Albert Ndaysaba, RW
PO46     Building a voice for metastatic breast cancer patients through a multi-year awareness campaign. Craig Faucette, CA
PO47     Creating a novel drug navigation tool for metastatic breast cancer drugs in Canada. Craig Faucette, CA
PO48     Share decision making for better patient participation in advanced breast cancer care. Marga Schrieks, NL
PO50     Coping with metastatic breast cancer: the patients’ perspective in a Brazilian cancer center. Maira Caleffi, BR
PO51     Clinical study to improve patient-hcp communication & engagement for newly diagnosed metastatic breast cancer patients. Corrine Ellsworth Beaumont, US
PO53     No lump required: a patient driven inflammatory breast cancer reserach initiative using the peer platform. Ginny Mason, US
PO54     The world is not enough: the twilight of MBC patients’ needs. Rania Azmi, KW
PO57     Mesenchymal circulating tumour cell analysis to predict efficacy of eribulin for metastatic breast cancer patients. Yoshiya Horimoto, JP
PO58     Regulation of stemness properties by ganoderma lucidum extract in inflammatory breast cancer cells via STAT3 regulation. Michelle Martinez Montemayor, PR
PO59     IL-2 mediated improvement of cell antitumor activity in advanced breast cancer patients. Sandra Radenkovic, RS
PO60     Influence of lipophilic components of matcha-tea extract on PPAR γ dependent cell proliferation. Lennard Schröder, DE
PO61     The identification of the genes concerning to the distant metastasis of TNBC - the interaction with AR as an index. Noriko Miwa, JP
PO63     Cancer associated fibroblasts display phenotypic and functional features that resemble circulating fibrocytes with constitute a nove subset of MDSCs. Gurcan Gunaydin, TR
PO68     First-line ribociclib plus letrozole for postmenopausal women with HR+, HER2-ABC: MANALEESA-2 safety results. Pierfranco Conte, IT
PO69     Overall survival and patient-reported impairment by fatigue, pain and treatment time in patients with advanced breast cancer in routine practice - results from the prospective German TMK cohort study. Norbert Marschner, DE
PO70     Herceptin alone in comparison with herceptin combined evorilimus in Asian patients with HER2+ breast cancer. Farrukh Djuraev, UZ
PO71     ERBB2 amplification level and PTPN2 gain as potential prognostic factors in metastatic HER2-positive breast cancer treated with trastuzumab. Sander Ellegard, SE
PO72     Triplet combination of endocrine therapy with CDK 4/6 inhibitor, ribociclib, and mTOR inhibitor, everolimus in HR+, HER2-ABC: results from the dose-expansion cohort. Aditya Bardia, US
PO73     Efficacy and safety of palbociclib (PAL) pus fulvestrant (F) by geographic region in women with endocrine-resistant hormone receptor-positive (HR+), human epiderman growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) from PALOMA-3. Nadia Harbeck, DE
PO74     Efficacy and safety of platinum and metronomic cyclophosphamide in triple negative breast cancer. Giulia Viale, IT
PO75     Retrospective analysis of advanced luminal breast cancer patients treated with endocrine therapy (ET) and palbociclib within a compassionate use programme. Christian Maurer, BE
PO76     Preliminary data from a prospective non-interventional study to characterize real-world treatment patterns and outcomes of women with ER +/HER2-advanced/ metastatic breast cancer. Nadia Harbeck, DE
PO77     Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): When care objectives meet patients’ need preliminary results of the VICTOR-6 study. Marina Elena Cazzaniga, IT
PO78     Randomized prospective study: Paclitaxel every-3-weekly paclitaxel and versus weekly vinorelbine in metastatic breast cancer. Lika Katselashvili, GE
PO79     Real world prescription patterns in metastatic HR+ breast cancer. Analysis from Instituto Nacional de Cancerologia, Mexico City. Claudia Arce Salinas, MX
PO80     Efficacy of first line regimens in metastatic breast cancer patients. Real world evidence from Instituto Nacional de Cancerologia, Mexico City. Maria Tereza Nieto-Coronel, MX
PO81     Ribociclib and endocrine therapy (ET) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER-2) breast cancer: The MONALEESA clinical trials program. Pierfranco Conte, IT
PO82     A phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive HR+/human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy - vinometro. Christoph Thomssen, DE
PO83     Prognostic factors in metastatic breast cancer patients to brain: retrospective analysis brain: retrospective analysis. Ahmed Gaballah, EG
PO84     Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): Focus on luminal cancers. Results from GIM13-AMBRA study. Marina Elena Cazzaniga, IT
PO85     Capecitabine and vinorelbine combination more effective as the first line treatment of advanced ER positive breast cancer. Loay Kassem, EG
PO86     Efficacy and toxicity of eribulin in real-life non-selected advanced breast cancer patients. Anne Sofie Brems-Eskildsen, DK
PO87     All oral combination of vinorelbine and capecitabile as a first line treatment in patients (pts) with metastatic breast cancer (MBC). Samir Shehata, EG
PO88     Efficacy of capecitabile monotherapy as treatment for real life patients with HER2-negative mestastatic breast cancer. Anne Sofie Brems Eskildsen, DK
PO90     Efficacy and safety of eribulin in combination with trastuzimab in HER2-positive metastatic breast cancer patients: real life experience. Elena Kovalenko, RU
PO91     Relapse and metastatic spread patterns in patients with HER2/neu positive breast cancer who underwent targeted therapy. Ekaterine Arkania, GE
PO92     Evaluation of pertuzumab treatment for metastatic breast cancer in a retrospective single institution study. Mitsugu Yamamoto, JP
PO93     Leptomeningeal metastases from breast cancer - are we overtreatening? decision algorithms and assuring breast care. Ana Leonor Matos, PT
PO94     Treatment of advanced breast cancer with T-DM1 in a cancer center. Filipa Ferreira Pereira, PT
PO95     Patterns of response to therapy in ER/PR positive metastatic breast cancer. Marie Sundquist, SE
PO96     Advanced breast cancer in young women: outcome of a Portuguese hospital. David da Silva Dias, PT
PO100     Gastrointestinal and other selected adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: A systematic review and meta-analysis. Kyrillus Shohdy, EG
PO112     Breast cancer liver metastases - when to operate. Vítor Devezas, PT
PO113     GISEL study group proposal: a phase II randomized clinical trial in breast cancer patients with skin metastases treated with or without electrochemotherapy (ECT) during the first line of treatment. Roberto Agresti, IT
PO114     Metastatic breast cancer patients who achieved clinical complete response after multidisciplinary therapy: clinical features from a single institution. Haruko Takuwa, JP
PO115     A novel and innovative "non-tunneling" technique of port insertion for chemotherapy infusion in advance breast cancer patients: a single center study in 130 patients. Abhinav Deshpande, IN
PO117     Electrochemoterapy (ECT) treatment in-patient with bone foot metastasis from breast: A case report. Daniele Screpis, IT
PO118     Five years overall survival of locally advanced triple-negative breast cancer in west Sumatera, Indonesia. Daan Khambri, IN
PO121     A retrospective cohort study to investigate association between preferences for future care and period of final chemotherapy administration before end-of-life. Sena Yamamoto, JP
PO122     Advanced stage breast cancer lifestyle and exercise (ABLE) feasibility study: Preliminary results. Lidia Delrieu, FR
PO123     Leaving a legacy: Half day retreat for young women living with metastatic breast cancer. Mary Ajango, US
PO125     The information and support needs of women with metastatic breast cancer who have dependant aged children: A study to inform service development to support women talk with and prepare their children. Maria Leadbeater, UK
PO126     Quality of life and psychosocial need of metastatic breast cancer patients. Tahir Mehmood, PK
PO127     Palliative care in Egypt: Challenges and opportunities. Mohamed Hablas, EG
PO128     G-CSF and G-CSF biosimilars: A meta-analysis of randomized clinical trials in breast cancer patients undergoing myelosuppressive chemotherapy. Giuseppe Curigliano, IT
PO129     Musculoskeletal pain and health-related quality of life among breast cancer patients: Evidence from south India. Asmin Sha, IN
PO130     Utilization of integrative supportive services in a specialized advanced breast cancer center. Timothy J. Pluard, US
PO131     Predictive factors for persistent pain in patients with advanced breast cancer receiving adjuvant therapy. Teodora Alexa-Stratulat, RO
PO132     Evaluation of health-related quality of life via the computer-based health evaluation system (CHES) for Japanese metastatic breast cancer patients: A single-center pilot study. Yuichiro Kikawa, JP
PO133     Exploring support networks and quality of life of metastatic breast cancer patient in Nigeria and Turkey. Runcie Chikeruba Wilson Chidebe, NG
PO134     Homestatic correlations in patients with breast and ovarian cancer. Elina Beleva, BG
PO136     First-line treatment modality for metastatic breast cancer: A single-institution outcome analysis by metastatic site and molecular type. Russell Burcombe, UK
PO137     Presentation and specific risk factors of inflammatory breast cancer (IBC): a multicenter Tunisian study. Nesrine Mejri Turki, TU
PO138     Preference of treatment decision-making in women with advanced breast cancer. Chikako Shimizu, JP
PO139     An investigation into the psycho-social benefits of women attending UK charity breast cancer care’s "living with secondary breast cancer" service: A group based psycho-educational intervention. Catherine Priestley, UK
PO140     Rise of metastatic breast cancer incidence in Lebanon: Effect of refugees and displaced people from Syria, and patients from war-torn Iraq. Nagi S. El Saghir, LB
PO141     Adjuvant therapies for breast cancer improve cure rates but appear to shorten post-metastatic survival. Nadia Harbeck, DE
PO142     Advanced breast cancer prevalence and related personal factors. Nanuli Ninashvili, GE
PO143     Inflammatory breast cancer: A single center experience from developing country. Pooja Khullar, IN
PO144     Clinicopathological characteristics, prognosis and issues in young women (<40 years old) with recurrent or metastatic breast cancer. Kaori Ushimado, JP
PO145     Harvesting population data to aid treatment decisions in heavily pre-treated advanced breast cancer. Sharon Hensley Alford, US